非小细胞肺癌患者中PIK3CA基因突变的临床特征和预后

摘要

目的:探讨非小细胞肺癌PIK3 CA基因突变的临床特征和预后.方法:回顾性分析16例PIK3 CA基因突变的非小细胞肺癌临床特征,Kaplan-Meier法计算生存率,Log-rank法进行生存率显著性检验.结果:非小细胞肺癌中PIK3 CA基因突变率3.09％(16/517),中位总生存时间23.0个月,其中复合突变12例,中位总生存时间28.0个月,单纯突变4例,中位总生存时间21.0个月,两者差异无统计学意义(P=0.06);伴随EGFR基因突变5例,中位总生存时间28.5个月,不伴随EGFR基因突变11例,中位总生存时间21个月(P=0.45);伴随TP53基因突变4例,中位总生存时间30.6个月,不伴随TP53基因突变12例,中位总生存时间21.0个月(P=0.51).结论:PIK3CA基因突变非小细胞肺癌临床特征上无特异性,但复合突变比单纯突变临床可能获益更多.%Objective:To investigate clinical features and prognosis of non-small cell lung cancer harboring PIK3CA mutations.Methods:We retrospectively reviewed clinical features from 16 patients with NSCLC,and the survival rate was calculated by Kaplan-Meier method and log-rank test was used to compare the survival rates.Results:PIK3CA gene mutation rate was 3.09％ (16/517) in non-small cell lung cancer,the median overall survival time was 23.0 months,including 12 cases compound mutation,the median overall survival time for 28 months,4 cases simple mutation,the median overall survival time for 21.0 months,but there were no statistical differences (P=0.06),with EGFR mutations in 5 cases,the median overall survival time for 28.5 months,and without EGFR mutations in 11 cases,the median overall survival time for 21.0 months (P=0.45),with TP53 mutations in 4 cases,the median overall survival time for 30.6 months,and without TP53 mutations in 12 cases,the medianoverall survival time for 21.0 months(P=0.51).Conclusion:There is no specific in PIK3CA gene mutations nonsmall cell lung cancer.Patients with complex mutations may be more benefit from therapy than those with single mutations.